abatacept与adalimumab在早期双血清阳性类风湿关节炎伴HLA-DRB1共享表位患者中的头对头比较:AMPLIFIED随机III期试验结果
AMPLIFIED试验为全球III期随机单盲头对头研究,纳入338例早期、MTX-IR、ACPA/RF/SE阳性的RA患者,比较abatacept与adalimumab。主要终点(SE阳性亚组第24周ACR50)未达到,两组ACR50分别为59%和60%(校正OR 1.0,95%CI 0.6-1.6),安全性和患者报告结局相似。
要点
- 在早期双血清阳性伴SE阳性的MTX-IR RA患者中,abatacept对比adalimumab未显示优效。
- 第24周ACR50两组相似(59% vs 60%,校正OR 1.0,95%CI 0.6-1.6)。
- 两种治疗安全性和患者报告结局(包括疼痛)改善相似。
核心结论
- 在早期RA、MTX-IR、ACPA/RF/SE阳性患者中,abatacept与adalimumab疗效相当,abatacept未显示明确优势。
- 两种治疗总体耐受良好,不良事件和严重不良事件发生率相似。
研究设计与样本
- AMPLIFIED(NCT04909801)为全球、III期、头对头、随机、单盲研究。
- 共随机338例早期RA、MTX-IR、ACPA/RF/SE阳性患者。
- 主要终点为SE阳性亚组第24周ACR50;探索性分析包括生物标志物、免疫细胞亚群和患者报告结局。
主要发现
- 主要终点未达到:第24周ACR50 abatacept组59%,adalimumab组60%(校正OR 1.0,95%CI 0.6-1.6)。
- 两组抗CCP2抗体、CRP和RF水平均下降。
- abatacept与adalimumab对免疫调节(包括B细胞稳态)的影响不同。
- 两组患者报告结局(包括疼痛)均改善。
- 不良事件发生率abatacept组58.0%,adalimumab组59.2%;严重不良事件分别为2.4%和3.6%。
关键数值与推荐
- 主要终点SE阳性亚组第24周ACR50:abatacept 59% vs adalimumab 60%,校正OR 1.0(95%CI 0.6-1.6)。
- 不良事件:abatacept 58.0% vs adalimumab 59.2%;严重不良事件:2.4% vs 3.6%。
临床怎么用
- 对于早期、MTX-IR、ACPA/RF/SE阳性的RA患者,abatacept与adalimumab均可作为治疗选择,疗效和安全性相似。
- 选择治疗时需综合考虑免疫调节差异、患者报告结局及个体化因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if patients with early rheumatoid arthritis (RA), an inadequate response to methotrexate (MTX-IR), dual seropositivity for anticitrullinated protein antibodies (ACPAs) and rheumatoid factor (RF), plus shared epitope (SE) human leukocyte antigen risk allele would show a superior response to abatacept vs adalimumab. METHODS: The AMPLIFIED trial (NCT04909801) was a global, phase 3, head-to-head, randomised, single-blind study designed to evaluate treatment response with abatacept vs adalimumab in patients with early RA and MTX-IR, with ACPA, RF, and SE positivity. The primary endpoint was a 50% improvement in the American College of Rheumatology criteria (ACR50) at week 24 in the SE-positive subgroup. Exploratory analyses included biomarkers, immune cell subsets, and patient-reported outcomes (PROs). RESULTS: In all, 338 patients were randomised. Most patients (96%) completed treatment. Baseline demographics, disease characteristics, and glucocorticoid use were balanced between arms. The primary endpoint was not met. ACR50 at week 24 was 59% with abatacept and 60% with adalimumab (adjusted odds ratio [95% CI]: 1.0 [0.6-1.6]). Levels of anti-cyclic citrullinated peptide 2, C-reactive protein, and RF decreased with both treatments. Abatacept and adalimumab had differential impacts on immune modulation, including B-cell homeostasis. Both treatments improved PROs, including pain. Abatacept and adalimumab demonstrated similar rates of adverse events (AEs; 58.0% vs 59.2%) and serious AEs (2.4% vs 3.6%). CONCLUSIONS: Patients responded well to both treatments, with no clear advantage of abatacept vs adalimumab. Most patients tolerated their assigned therapies.
引用
- Emery P, Weinblatt ME, Bykerk VP, et al. A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial. Ann Rheum Dis. 2026. PMID: 42425800. doi:10.1016/j.ard.2026.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。